Dexcom (DXCM) Q1 2026: International Revenue Jumps 26% as Coverage Expansion Drives Durable Growth
Dexcom’s first quarter highlighted the accelerating impact of international expansion and new product launches, with a notable 26% surge in international revenue and robust share gains in U.S. type 2 diabetes segments. Margin discipline and operational leverage set the stage for sustained outperformance, even as the company navigates coverage unlocks and macro pressures. Upcoming clinical data and payer decisions hold the key to the next phase of growth.
Summary
- International Access Expansion: Recent reimbursement wins and tailored product launches are fueling outsized growth abroad.
- Type 2 Diabetes Share Gains: U.S. momentum is increasingly driven by penetration in non-insulin populations and new coverage wins.
- Margin Resilience: Operational improvements and cost discipline are offsetting inflationary headwinds and supporting guidance raises.
Performance Analysis
Dexcom delivered strong Q1 results, with total revenue up 15% and organic growth of 12%, reflecting broad-based demand for its continuous glucose monitoring (CGM) systems. The U.S. business posted 11% growth, powered by increased adoption in type 2 diabetes and the launch of the G7 15-day product, which is rapidly converting the installed base and attracting new starts. International markets outperformed, with revenue up 26% and organic growth of 17%, led by markets like France and Canada where reimbursement access has recently expanded.
Gross margin improved sharply to 63.5%, up 600 basis points year over year, driven by manufacturing efficiencies, lower freight costs, and the favorable impact of the G7 15-day rollout. Operating income and adjusted EBITDA margins also saw significant expansion, reflecting disciplined cost management. Free cash flow was notably strong, boosting Dexcom’s cash balance by $400 million and providing ample capital flexibility.
- International Outperformance: Recent wins in reimbursement and dual-formulary tenders are unlocking new cohorts and driving above-market growth in core geographies.
- G7 15-Day Uptake: The new sensor’s longer wear and improved accuracy are accelerating both new patient starts and base conversions, with management targeting 50% conversion by year-end.
- Margin Leverage: Sustained operational improvements are enabling margin expansion even amid inflationary risks from fuel and resin costs.
Dexcom’s first quarter results demonstrate an ability to grow both core and emerging segments while maintaining financial discipline and investing in future growth levers.
Executive Commentary
"This was especially pronounced across the categories of type 2 diabetes, where our expanded reach and product momentum led to strong first quarter share gains, with the biggest increase coming from people with type 2 diabetes who are not on insulin."
Jake Leach, President and Chief Executive Officer
"Our international growth was widespread across our core markets this quarter, with some of the largest increases coming from geographies where we have recently expanded access, such as France and Canada."
Jeremy Sylvain, Chief Financial Officer
Strategic Positioning
1. U.S. Type 2 Diabetes Expansion
Dexcom is aggressively targeting the underpenetrated type 2 diabetes population, particularly non-insulin users, leveraging recent commercial coverage gains. The addition of Prime Therapeutics will bring coverage to over 7 million non-insulin lives by year-end, and management expects further momentum as CMS (Centers for Medicare & Medicaid Services) expands coverage—a move viewed as inevitable and transformative for long-term growth.
2. Product Innovation and Ecosystem Development
The G7 15-day system is reshaping user experience and driving adoption, with a new sensor algorithm delivering record accuracy and positive feedback from both patients and physicians. Ongoing product innovation includes new adhesive technology for improved sensor survivability, software updates such as a major Stello app redesign, and the Smart Basal personalized dosing feature, all aimed at deepening engagement and retention.
3. International Growth Strategy
Dexcom’s tailored portfolio approach is unlocking share in international markets, with recent reimbursement wins and dual-formulary tender access increasing penetration. The upcoming international launch of Stello and a new CGM system are set to further extend reach, with management highlighting the repeat-use nature of tenders and the stickiness of the customer base as growth drivers.
4. Margin and Cost Structure Discipline
Operational improvements, manufacturing efficiencies, and disciplined expense management are supporting margin expansion, despite inflationary pressures from oil, fuel, and resin costs. Management remains cautious on gross margin guidance due to macro uncertainties but raised operating and EBITDA margin targets, reflecting confidence in underlying execution.
5. Capital Allocation and Balance Sheet Strength
With over $2.4 billion in cash and robust free cash flow generation, Dexcom is positioned for both organic investment and opportunistic M&A. The company has demonstrated flexibility via recent share buybacks and debt repayment, and plans to outline further capital allocation priorities at its upcoming Investor Day.
Key Considerations
Dexcom’s Q1 performance underscores its ability to capture share in both established and emerging diabetes segments while maintaining operational excellence and financial flexibility. The business is in a transition phase, with multiple levers—coverage expansion, product innovation, and international access—all contributing to a durable, diversified growth profile.
Key Considerations:
- Coverage Expansion Impact: Each new payer unlock, especially in type 2 non-insulin, drives incremental volume and deepens Dexcom’s competitive moat.
- Product Differentiation: The G7 15-day launch and upcoming Smart Basal feature reinforce Dexcom’s technology leadership and user retention.
- Operational Leverage: Margin gains are being realized even as the company invests in R&D, manufacturing scale (Ireland facility), and digital platforms.
- CMS and Regulatory Catalysts: The timing and breadth of CMS coverage for type 2 non-insulin will define the next leg of U.S. growth and competitive dynamics.
- International Playbook: Success in tenders and dual-formulary access is proving repeatable, with further upside as Stello and new CGM systems launch abroad.
Risks
Key risks include the timing and scope of CMS coverage for type 2 non-insulin, which remains uncertain and could affect the growth trajectory if delayed or restricted. Inflationary pressures on input costs (fuel, resin) present ongoing margin headwinds, and competitive dynamics—especially in the U.S.—may intensify as market penetration increases. Regulatory or reimbursement setbacks in key international markets could also impact expansion plans.
Forward Outlook
For Q2 2026, Dexcom maintained its stance of balanced growth between U.S. and international markets, with management noting:
- Continued momentum from G7 15-day conversions and new patient starts
- Further coverage unlocks, including Prime Therapeutics, expected to begin contributing this summer
For full-year 2026, management reaffirmed revenue guidance of $5.16 to $5.25 billion (11% to 13% growth) and gross margin guidance of 63% to 64%, while raising operating and EBITDA margin guidance to 23%–23.5% and 31%–31.5%, respectively. Key drivers include ongoing product launches, coverage expansion, and disciplined cost management, with macro risks from fuel and shipping costs factored into guidance.
Takeaways
Dexcom’s Q1 results reflect a business executing on multiple fronts—coverage expansion, product innovation, and disciplined operations—while positioning itself for the next phase of durable growth.
- International and Type 2 U.S. Growth Engines: Outperformance in international markets and share gains in U.S. type 2 diabetes are offsetting slower legacy segments and building a diversified growth base.
- Margin and Cash Flow Strength: Operational leverage and cost discipline are delivering improved profitability and financial flexibility, supporting both investment and capital return.
- CMS and Clinical Data as Catalysts: The upcoming RCT readout and potential CMS coverage decision are pivotal events that could unlock the next leg of growth and reshape the competitive landscape.
Conclusion
Dexcom’s Q1 2026 performance showcases the company’s ability to drive growth through coverage expansion, innovation, and international execution while maintaining operational discipline. With major catalysts ahead in clinical evidence and reimbursement, the business is well-positioned for continued leadership in CGM.
Industry Read-Through
Dexcom’s results and commentary highlight a broader industry shift toward expanding CGM access beyond insulin-intensive diabetes populations, with payer coverage and real-world evidence increasingly driving adoption. The success of longer-wear sensors and digital engagement tools signals rising consumer expectations for ease of use and actionable insights. For peers and new entrants, the playbook of combining reimbursement wins, product differentiation, and operational excellence will be critical. The timing and scope of CMS decisions will set the pace for U.S. market expansion, while international tender dynamics and product localization remain key levers for global growth across the medtech sector.